Objective This survey aims to explore the current medical treatment of major depressive
disorder (MDD) in China and match its degree with Canadian Network for Mood and Anxiety …

The surveillance search since the inaugural review was published covers the search
periods from 8 August 2022 to 22 August 2023. To inform the surveillance search, we …

Background: The Canadian Network for Mood and Anxiety Treatments (CANMAT)
conducted a revision of the 2009 guidelines by updating the evidence and …

Background: Antidepressant (AD) algorithm is an important tool to support treatment
decision-making and improve management of major depressive disorder (MDD). However …

Background The recent guidelines for depressive disorders in China are based on both the
first edition published in 2003, and new scientific evidence reviewed until the end of 2014 …

Abstract The Korean Medication Algorithm Project for Depressive Disorder (KMAP-DD) first
was published in 2002, and has been revised four times, in 2006, 2012, 2017, and 2021. In …

In this review, we compared recommendations from the Korean Medication Algorithm
Project for Depressive Disorder 2017 (KMAP-DD 2017) to other global treatment guidelines …

Purpose In the treatment guidelines for major depressive disorder (MDD), the recommended
treatment differs based on the severity. However, the type of treatment provided based on …

Depression has brought huge disease burden to the world. This systematic review aimed to
compare the efficacy and safety of pharmacological and non-pharmacological treatments for …

Objectives This study aims to summarise the evidence on more than 140 pharmacological
and non-pharmacological treatment options for major depressive disorder (MDD) and to …